SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales moved down -67.58% to Rs. 41.67 millions for the September 2025 quarter as compared to Rs. 128.55 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2025 is Rs. -61.43 millions as compared to Net Loss of Rs. -57.61 millions of corresponding quarter ended September 2024 Operating profit Margin for the quarter ended September 2025 further decreased to -27.86% as compared to -26.24% of corresponding quarter ended September 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 41.67 128.55 -67.58 96.48 257.44 -62.52 433.12 504.22 -14.10
Other Income 0.07 0.86 -91.86 0.19 1.20 -84.17 7.09 4.51 57.21
PBIDT -27.86 -26.24 6.17 -48.61 -47.87 1.55 -143.21 -82.72 73.13
Interest 17.33 14.25 21.61 33.83 27.43 23.33 59.14 46.89 26.12
PBDT -45.19 -40.49 11.61 -82.44 -75.30 9.48 -202.35 -129.61 56.12
Depreciation 16.24 17.12 -5.14 32.23 34.02 -5.26 66.89 67.66 -1.14
PBT -61.43 -57.61 6.63 -114.67 -109.32 4.89 -269.24 -197.27 36.48
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -61.43 -57.61 6.63 -114.67 -109.32 4.89 -269.39 -197.27 36.56
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -66.86 -20.41 227.54 -50.38 -18.59 170.96 -33.06 -16.41 101.55

Krebs Biochem.&Inds Share Price

64.06 0.87 (1.38%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: